End-of-day quote
Shanghai S.E.
06:00:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
24.29
CNY
|
+3.05%
|
|
+5.47%
|
+6.21%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,993
|
11,142
|
12,993
|
13,828
|
-
|
-
|
Enterprise Value (EV)
1 |
13,993
|
11,142
|
12,993
|
13,828
|
13,828
|
13,828
|
P/E ratio
|
65.2
x
|
11
x
|
36.9
x
|
28.7
x
|
21.5
x
|
16.6
x
|
Yield
|
1.16%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11.9
x
|
-
|
6.33
x
|
6.1
x
|
4.92
x
|
3.94
x
|
EV / Revenue
|
11.9
x
|
-
|
6.33
x
|
6.1
x
|
4.92
x
|
3.94
x
|
EV / EBITDA
|
-
|
-
|
23.9
x
|
18.7
x
|
14
x
|
11.7
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
9.17
x
|
-
|
5.08
x
|
4.69
x
|
3.89
x
|
3.28
x
|
Nbr of stocks (in thousands)
|
567,000
|
567,000
|
568,129
|
569,276
|
-
|
-
|
Reference price
2 |
24.68
|
19.65
|
22.87
|
24.29
|
24.29
|
24.29
|
Announcement Date
|
2/18/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1,178
|
-
|
2,053
|
2,268
|
2,811
|
3,509
|
EBITDA
1 |
-
|
-
|
-
|
543.4
|
739.6
|
985.3
|
1,182
|
EBIT
1 |
-
|
226.8
|
-
|
340.5
|
522.8
|
704.5
|
870.2
|
Operating Margin
|
-
|
19.26%
|
-
|
16.59%
|
23.05%
|
25.06%
|
24.8%
|
Earnings before Tax (EBT)
1 |
-
|
227.8
|
-
|
330.1
|
518.1
|
699.4
|
864.3
|
Net income
1 |
210.5
|
204.7
|
-
|
358.4
|
481.4
|
644.2
|
832.9
|
Net margin
|
-
|
17.38%
|
-
|
17.46%
|
21.23%
|
22.92%
|
23.74%
|
EPS
2 |
0.4143
|
0.3786
|
1.780
|
0.6200
|
0.8460
|
1.132
|
1.468
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.2857
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/22/21
|
2/18/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
---|
Net sales
1 |
431.3
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
66.03
|
Net margin
|
15.31%
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
4/19/24
|
Fiscal Period: December |
2020
|
2021
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
17.2%
|
14.3%
|
15.7%
|
17.8%
|
19.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
9.46%
|
11.6%
|
13.7%
|
14.8%
|
Assets
1 |
-
|
-
|
3,789
|
4,150
|
4,702
|
5,628
|
Book Value Per Share
2 |
-
|
2.690
|
4.510
|
5.180
|
6.240
|
7.400
|
Cash Flow per Share
2 |
-
|
0.4600
|
-0.1300
|
1.200
|
1.220
|
1.520
|
Capex
1 |
-
|
373
|
663
|
412
|
373
|
482
|
Capex / Sales
|
-
|
31.64%
|
32.28%
|
18.15%
|
13.28%
|
13.73%
|
Announcement Date
|
4/22/21
|
2/18/22
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
24.29
CNY Average target price
30.22
CNY Spread / Average Target +24.42% Consensus |
1st Jan change
|
Capi.
|
---|
| +6.21% | 1.91B | | +75.69% | 12.57B | | -24.68% | 7.34B | | +6.22% | 6.61B | | +12.58% | 5.39B | | +26.90% | 4.53B | | -21.14% | 3.91B | | -22.99% | 2.91B | | +47.42% | 2.37B | | -0.37% | 2B |
Medical Equipment
|